Innate Pharma S.A.
IPHYF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | 0.71 | -0.01 | 0.01 |
| FCF Yield | -22.10% | -4.42% | 1.92% | -10.21% |
| EV / EBITDA | -4.57 | -8.97 | -4.27 | -16.96 |
| Quality | ||||
| ROIC | -35.10% | -29.11% | -21.53% | -8.49% |
| Gross Margin | -322.22% | 10,634.78% | -135.53% | -14.58% |
| Cash Conversion Ratio | 1.46 | 0.40 | -0.12 | 2.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -22.47% | -16.11% | -21.45% | -11.95% |
| Free Cash Flow Growth | -210.98% | -464.69% | 113.03% | -79.46% |
| Safety | ||||
| Net Debt / EBITDA | 1.06 | 1.66 | 1.35 | 2.95 |
| Interest Coverage | 0.00 | -44.63 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -13.24 | 560.29 | -24.22 | 163.76 |